Johnson and Johnson and AZ Study if Modifying Vaccines Can Reduce Risk of Blood clots 

Johnson & Johnson and AstraZeneca are studying whether modifying their COVID-19 vaccines can reduce or eliminate the risk of rare blood clots

  • Johnson & Johnson and AstraZeneca-University of Oxford have begun studying whether their COVID-19 vaccines can be modified
  • Both shots have been linked to a risk of blood clots along with a low platelet-count condition known as thrombocytopenia
  • Scientists hope to identify the causes behind the blood clots and maybe re-engineer the shots by next year
  • In the U.S., J&J’s vaccine has been linked to 0.3 cases of rare blood clots per 100,000 doses and AstraZeneca’s jab linked to 1-2 cases per 100,000
  • It comes one day after it was revealed the FDA is adding a new warning to the label of J&J’s vaccine due the risk of a rare autoimmune disorder.

Click through to read the rest of the article.

Share this:

What do you think?

Posted by Lady Bay

Concerned citizen.


Leave a Reply

Leave a Reply

Your email address will not be published. Required fields are marked *

Coronavirus: Thai doctors want Pfizer vaccines amid doubts over Sinovac’s efficacy against Delta variant

M 5.1 – 42 km NNW of Neiafu, Tonga